Avudin Tablet

About Avudin 150 mg + 300 mg Tablet

Avudin is a tablet combining lamivudine and zidovudine, used with other antiretroviral medicines to treat HIV-1 infection. It is a prescription medicine and the doctor decides the dose and course.

What is Avudin 150 mg + 300 mg Tablet?

Avudin is a tablet made by Square Pharmaceuticals PLC. Each tablet contains 150 mg lamivudine and 300 mg zidovudine. Both are nucleoside analogue reverse transcriptase inhibitors, a type of anti-retroviral medicine. The tablet is used in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is not used alone. The doctor decides the dose and course. The listed pack is 1 x 10 tablets. Store in a cool, dry place away from light and moisture, and keep out of the reach of children.

Uses of Avudin

Avudin is used, together with other anti-retroviral medicines, for the treatment of HIV-1 infection in adults and adolescents. It contains two anti-retroviral drugs, lamivudine and zidovudine. It is not a stand-alone treatment and should not be used without the other medicines your doctor prescribes. Ask your doctor how it fits into your treatment plan.

How to use Avudin

Take Avudin exactly as your doctor tells you. The doctor decides the dose and course. Swallow the tablet as directed. Do not change the dose or stop taking it without talking to your doctor, because HIV treatment must be followed consistently. If you miss a dose, ask your doctor or pharmacist what to do. Keep the tablets in their pack and store them in a cool, dry place protected from light and moisture.

Side effects of Avudin

Some people may have side effects. More common ones include chills, fever, pale skin, sore throat, unusual tiredness or weakness, and headache. Less common ones include abdominal pain, burning, tingling, numbness or pain in the hands, arms, feet or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, and yellow eyes or skin. Coughing, decreased appetite, diarrhoea, dizziness and trouble sleeping may also occur. Tell your doctor if any side effect bothers you.

Safety and precautions

Do not take Avudin if you have had a significant allergic reaction to lamivudine, zidovudine or any part of the tablet. People with low body weight should not receive this combination; the doctor will advise. Tell your doctor if you have kidney problems, liver problems, or HIV with hepatitis B infection, as extra monitoring may be needed. Pregnancy category C: use in pregnancy only if the doctor decides the benefits outweigh the risks. Mothers should not breast-feed while taking HIV medicines, to avoid passing HIV to the baby. Ask your doctor before starting.

Frequently asked questions

What is the price of Avudin?

The listed price is ৳ 45.00.

Who should avoid Avudin or ask the doctor first?

Anyone with a known serious allergy to lamivudine, zidovudine or any ingredient should not take it. People with low body weight should not receive this combination. Ask your doctor first if you have kidney or liver problems, hepatitis B coinfection, or are pregnant or breast-feeding.

What is Avudin used for and what kind of medicine is it?

Avudin is an anti-retroviral tablet used with other medicines to treat HIV-1 infection. It contains two nucleoside analogue reverse transcriptase inhibitors, lamivudine and zidovudine. It is not used alone. Your doctor decides the dose and course.

What does the generic name lamivudine + zidovudine mean?

The generic name shows the two active ingredients in the tablet: lamivudine 150 mg and zidovudine 300 mg. Both are anti-retroviral drugs that work against HIV. The doctor decides how the medicine is used in your treatment.

Indications

Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection

Pharmacology

Lamivudine and Zidovudine are synthetic nucleoside analogues with activity against human immunodeficiency virus (HIV).

Lamivudine: Intracellularly, Lamivudine is phosphorylated to its active 5’-triphosphate metabolite, Lamivudine triphosphate (L-TP). The principal mode of action of L-TP is inhibition of reverse transcription (RT) via DNA chain termination after incorporation of the nucleoside analogue. Following oral administration, Lamivudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low.

Zidovudine: Intracellularly, Zidovudine is phosphorylated to its active 5’-triphosphate metabolite, Zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleoside analogue. Following oral administration, Zidovudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Zidovudine is eliminated primarily by hepatic metabolism.

Dosage & Administration

Recommended Dosage for Adults and Adolescents: The recommended dosage of lamivudine and zidovudine tablets in HIV-1-infected adults and adolescents weighing greater than or equal to 30 kg is 1 tablet (containing 150 mg of lamivudine and 300 mg of zidovudine) taken orally twice daily.

Recommended Dosage for Pediatric Patients: The recommended dosage of lamivudine and zidovudine tablets for pediatric patients who weigh greater than or equal to 30 kg and for whom a solid oral dosage form is appropriate is 1 tablet administered orally twice daily on an empty stomach. Before prescribing lamivudine and zidovudine tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow a lamivudine and zidovudine tablet, the liquid oral formulations should be prescribed.

Not Recommended Due to Lack of Dosage Adjustment Because lamivudine and zidovudine tablets are a fixed-dose formulation and cannot be dose adjusted, lamivudine and zidovudine tablets are not recommended for:
  • Pediatric patients weighing less than 30 kg 
  • Patients with creatinine clearance less than 50 mL per minute
  • Patients with hepatic impairment
  • Patients experiencing dose-limiting adverse reactions. Liquid and solid oral formulations of the individual components of lamivudine and zidovudine tablets are available for these populations.

Interaction

Cross-resistance may develop when given with emtricitabine. Exacerbation of anaemia with concomitant use of zidovudine with ribavirin. Increased adverse effects to zidovudine with nephrotoxic or myelosuppressive drugs (e.g. systemic pentamide, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine, doxorubicin). Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another. Antagonistic effect when zidovudine is used concomitantly with stavudine or doxorubicin.

Contraindications

This is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of the product. Reduction of doses of Lamivudine is recommended for patients with low body weight (less than 50 kg or 110 lb); therefore, patients with low body weight should not receive Lamivudine & Zidovudine.

Side Effects

Side effects of this medicine-
  • More common: Chills, fever, pale skin; sore throat; unusual tiredness or weakness, headache
  • Less common: Abdominal pain, burning, tingling, numbness, or pain in the hands, arms, feet, or legs, muscle tenderness and weakness, nausea, skin rash, vomiting, yellow eyes or skin. Coughing, decreased appetite, diarrhea, dizziness and trouble in sleeping may occurs

Pregnancy & Lactation

Pregnancy Category C. There arc no adequate and well controlled studies of this drug in pregnant women. This drug should be used during pregnancy only if the potential benefits outweigh the risks. The Centers for Disease Control and Prevention recommend that HIV-infected mothers should not breast-feed their infants to avoid risking postnatal transmission of HIV. Because of the potential for HIV transmission and the potential for serious adverse effects in nursing infants, mothers should be instructed not to breast feed if they are receiving efavirenz.

Precautions & Warnings

Patients with HIV and Hepatitis B virus Coinfection: Safety and efficacy of Lamivudine have not been established for treatment of chronic hepatitis B in patients dually infected with HIV and HBV. Emergence of hepatitis B virus variants associated with resistance to Lamivudine has also been reported in HIV-infected patients who have received Lamivuuine-containing antiretroviral regimens in the presence of concurrent infection with Hepatitis B virus. Post-treatment exacerbations of hepatitis have also been reported.

Patients with Impaired Renal Function: Reduction of the dosages of Lamivudine and Zidovudine is recommended for patients with impaired renal function. Patients with creatinine clearance <50 ml/min should not receive this combination tablet.

Fat Redistribution: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast
enlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.

Storage Conditions

Stored at a cool and dry place, protected from light and moisture. Keep the medicine out of the reach of children.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.